DSIP — Apex Research Reference

01 / IDENTITY

Compound Profile

9

AMINO ACIDS

~0.85

kDa MW

SC

ROUTE

Endogenous

ORIGIN

SEQUENCE

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

CLASSIFICATION

Endogenous nonapeptide first isolated from rabbit brain. Naturally produced in the hypothalamus and found in human blood. Crosses the blood-brain barrier. Modulates sleep architecture, GH secretion, stress response, and LH pulsatility.

MECHANISM

Multiple mechanisms: promotes slow-wave (delta) sleep via hypothalamic modulation; stimulates GH pulsatile release; inhibits corticotrophin (ACTH) and reduces cortisol stress response; modulates LH pulsatility (relevant for testosterone in males); antioxidant properties via direct ROS scavenging.

DISCOVERED

Marcel Monnier, University of Basel, 1977 — isolated from rabbit cerebral venous blood during slow-wave sleep. Named for its ability to induce delta-wave EEG patterns when administered to test animals.

VIAL SIZE

10mg lyophilized powder

UNIQUE PROPERTY

Unlike sedatives/hypnotics, DSIP improves sleep quality without causing sedation as a side effect. It normalizes sleep architecture rather than forcing sleep via CNS depression. Non-habit forming. No morning grogginess.

02 / RESEARCH HISTORY

Development Timeline

1977

Marcel Monnier and Ludwig Schoenenberger at the University of Basel publish the discovery of DSIP — isolated from the cerebral venous blood of rabbits during induced slow-wave sleep. EEG recording confirms the isolated peptide induces delta-wave sleep when administered to naive recipient animals. Named Delta Sleep-Inducing Peptide.

1980s

DSIP identified in human blood, urine, and CSF — confirming it is an endogenous human neuropeptide, not just a rabbit protein. Research expands: DSIP found in pituitary, hypothalamus, adrenal glands, testes, and pancreas — suggesting systemic functions beyond sleep. Multiple research groups in Europe and USSR investigate.

1984–1990

Valdman AV and colleagues (USSR) establish DSIP's anti-stress properties — reduces cortisol, normalizes ACTH response to stress, and prevents stress-induced pathology in animal models. Soviet military research into DSIP for stress resilience documented. Simultaneously, Schoenenberger's group publishes GH-stimulating effects.

1990–2005

Human clinical studies in Europe for insomnia, opiate withdrawal (DSIP reduces withdrawal severity), and chronic pain. Small but consistent results. Limited pharmaceutical interest due to short half-life and low oral bioavailability — large pharma moves toward synthetic small molecule sleep aids instead (Z-drugs).

2010–present

Performance and longevity community adopts DSIP for sleep quality improvement, GH pulsation enhancement, and cortisol management. Recognized as safer alternative to sleep medications for athletes. Stacking with GH peptides (Ipamorelin/CJC-1295) for synergistic sleep + GH pulse protocol becomes popular.

03 / BENEFITS

Primary Effects

01

Slow-Wave Sleep Enhancement

DSIP increases the proportion of slow-wave (delta) sleep — the deepest, most restorative sleep stage. SWS is when GH secretion peaks, tissue repair occurs, and memory consolidation happens. DSIP does this by normalizing sleep architecture, not sedating — users wake feeling genuinely rested, not groggy. Particularly effective for those with poor SWS due to age, stress, or overtraining.

02

GH Pulse Amplification

DSIP stimulates pituitary GH secretion in a pulsatile pattern. The largest natural GH pulse occurs 60–90 minutes after sleep onset during the first SWS cycle. DSIP both deepens SWS and directly stimulates GH release — creating a compounding effect. Synergistic when combined with Ipamorelin or CJC-1295 at bedtime.

03

Stress Response Normalization

DSIP inhibits ACTH-induced cortisol release. In chronically stressed individuals (elevated cortisol patterns), DSIP normalizes the HPA axis. This stress-buffering effect is documented across multiple species and some human data — reducing both acute stress response magnitude and restoring normal diurnal cortisol rhythms.

04

LH Pulsatility & Testosterone Support

DSIP modulates hypothalamic GnRH pulsatility, which directly affects LH secretion. LH is the primary driver of testicular testosterone production. Improved LH pulsatility → normalized testosterone production. Relevant for post-cycle support and age-related testosterone decline.

05

Antioxidant Activity

DSIP has direct antioxidant properties — scavenges superoxide and hydroxyl radicals. Reduces lipid peroxidation in neuronal membranes. Neuroprotective in oxidative stress models. An underappreciated aspect of its recovery-enhancing profile.

06

Opiate & Alcohol Withdrawal Support

Human clinical data shows DSIP reduces the severity of opiate and alcohol withdrawal symptoms. Mechanism: normalizes dysregulated HPA axis and sleep architecture that are severely disrupted in withdrawal states. Used in some European addiction medicine protocols.

04 / RECONSTITUTION

Preparation Protocol

// 10MG VIAL — STANDARD RECONSTITUTION

10,000 mcg ÷ 300 units BAC water = 33.3 mcg per unit

Add 3.0 mL (300 units) bacteriostatic water to 10mg lyophilized vial.

TARGET DOSE	UNITS TO DRAW	VOLUME	NOTE
LOW100 mcg	3 units	0.03 mL	Sensitive users; first-time use
STANDARD250 mcg	7.5 units	0.075 mL	Most common dose in clinical studies
HIGH500 mcg	15 units	0.15 mL	Upper dose; refractory insomnia protocols

Storage: Lyophilized — refrigerate (2–8°C), protect from light and moisture. Reconstituted: refrigerate, use within 30 days. DSIP is relatively stable once reconstituted.

05 / DOSING PROTOCOL

Administration Guide

PROTOCOL	DOSE	TIMING	DURATION	CONTEXT
SLEEP ONLY	250 mcg SC	30 min before bed	Ongoing / nightly	Sleep quality improvement, recovery
GH STACK	250 mcg SC	With Ipa/CJC at bedtime	8–12 weeks	GH pulse + SWS synergy
STRESS	100–250 mcg SC	Evening (cortisol correction)	4–8 weeks	HPA axis normalization, overtraining recovery
CYCLING	250 mcg SC	5 nights on / 2 off	Ongoing	Long-term use without tolerance

No sedation side effect: DSIP does not cause daytime drowsiness, cognitive impairment, or dependence. Unlike benzodiazepines or Z-drugs, DSIP works with your natural sleep biology. Users report feeling genuinely rested rather than artificially sedated.

06 / TIMING

Administration Timing

INJECTION TIME

30–60 minutes before intended sleep time. Aligns with natural DSIP release patterns. Allows time for hypothalamic effects before the first SWS cycle begins.

FASTED STATE

Inject fasted or 2+ hours after last meal. Food (especially carbohydrates) raises insulin which can blunt the GH pulse that DSIP helps generate. Consistent with the broader Ipamorelin/CJC fasting protocol.

STACKING TIMING

Co-administer with Ipamorelin (200mcg) + CJC-1295 no DAC (200mcg) at bedtime for maximal GH pulse. All three in one injection is acceptable — use separate syringe if mixing, or inject simultaneously at same site.

FREQUENCY

Nightly for 5 nights, 2 nights off OR every night. No tolerance development has been documented in DSIP use. Unlike melatonin, tolerance to DSIP's sleep effects does not appear to occur.

07 / BIOMARKERS

Monitoring Panel

// SLEEP & RECOVERY MARKERS

MARKER	TEST	CLINICAL RANGE	OPTIMAL ON DSIP
SWS Duration (slow-wave sleep)Sleep Architecture	Wearable (Oura Ring, Whoop) or PSG	CLIN20–25% of total sleep time	OPT25–30% SWS; increasing trend on DSIP
HRV (Heart Rate Variability)Autonomic Recovery	Wearable (Oura, Garmin, Polar)	CLINIndividual baseline dependent	OPTImproving trend vs. personal baseline; >+5ms from pre-DSIP
Sleep EfficiencyTime Asleep/Time in Bed	Wearable tracker	CLIN>85%	OPT>90%

// HORMONAL MARKERS

MARKER	TEST	CLINICAL RANGE	OPTIMAL
AM CortisolMorning Cortisol Peak	AM serum (8 AM)	CLIN6–23 mcg/dL	OPT10–18 mcg/dL (robust but not elevated) — DSIP normalizes HPA pattern
PM CortisolEvening Cortisol Trough	PM serum or salivary (4–8 PM)	CLIN<5 mcg/dL (evening)	OPT<3 mcg/dL (deep evening trough = good rhythm)
IGF-1GH Axis Proxy	AM serum	CLINAge-adjusted normal range	OPTUpper-normal for age (reflects improved GH pulsation during sleep)
LHLuteinizing Hormone	Morning serum	CLIN1.7–8.6 IU/L (males)	OPTNormalized pulsatility; mid-normal to upper range

08 / CYCLE PROTOCOL

Recommended Cycle

Ongoing

DURATION

5–7×

NIGHTS/WEEK

None

REQUIRED OFF

Night

INJECTION TIME

Standard Protocol: 250mcg SC, 30 minutes before sleep, 5–7 nights per week. No required off period — DSIP does not cause downregulation or tolerance. Many users run continuously during training blocks or periods of high stress/poor sleep.

GH Stack Protocol: 250mcg DSIP + 200mcg Ipamorelin + 200mcg CJC-1295 no DAC, all subcutaneous, fasted, 30–60 min before bed. This is one of the most effective recovery-optimization stacks available — deep SWS + maximal GH pulse + cortisol normalization all in one bedtime protocol.

Stress/Overtraining Recovery: Athletes experiencing overtraining syndrome (elevated resting HR, poor sleep, mood disruption, performance decline) often respond dramatically to DSIP. Run 250mcg nightly for 3–4 weeks alongside a deload phase. Restores normal HPA rhythms and sleep architecture faster than rest alone.

Research Compound Notice: DSIP is an endogenous human peptide with human clinical data for sleep improvement and opiate withdrawal. It has not been approved by the FDA as a drug. The existing human clinical data is from small European studies, primarily 1980s–1990s. Long-term safety profile is considered favorable given its endogenous nature and lack of reported adverse effects across decades of research and clinical use. Consult a healthcare provider.